| Biological Sciences | 2021-2025 | 36 | CN 11 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 161 | CN 16 | 99.97 |
| Clinical Biochemistry | Lifetime | 10 | CN 1 | 99.74 |
| Pulmonary and Respiratory Medicine | Lifetime | 123 | CN 3 | 99.84 |
| Molecular Biology | Lifetime | 898 | CN 44 | 99.52 |
| Epidemiology | Lifetime | 717 | CN 21 | 99.06 |
| Cancer Research | Lifetime | 419 | CN 34 | 97.45 |
| Immunology | Lifetime | 838 | CN 26 | 97.27 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 4 | CN 1 | 99.98 |
| Molecular Biology | 2021-2025 | 17 | CN 9 | 99.93 |
| Immunology | 2021-2025 | 36 | CN 6 | 99.24 |
| Cancer Research | 2021-2025 | 31 | CN 13 | 98.77 |
| Epidemiology | 2021-2025 | 288 | CN 29 | 97.68 |
| Clinical Biochemistry | 2021-2025 | 18 | CN 3 | 94.25 |
| Oncology | 2021-2025 | 361 | CN 42 | 96.06 |
| Nutrition and Dietetics | 2021-2025 | 267 | CN 85 | 90.33 |
| Ferroptosis and cancer prognosis | Lifetime | 1 | CN 1 | 99.93 |
| Advanced Glycation End Products research | Lifetime | 3 | CN 1 | 99.86 |
| RNA modifications and cancer | Lifetime | 29 | CN 2 | 99.87 |
| Autophagy in Disease and Therapy | Lifetime | 15 | CN 1 | 99.86 |
| Cancer, Lipids, and Metabolism | Lifetime | 34 | CN 1 | 99.80 |
| Heme Oxygenase-1 and Carbon Monoxide | Lifetime | 32 | CN 2 | 99.16 |
| Inflammasome and immune disorders | Lifetime | 47 | CN 3 | 99.28 |
| Immune cells in cancer | Lifetime | 111 | CN 8 | 99.23 |
| Cancer-related molecular mechanisms research | Lifetime | 443 | CN 202 | 98.57 |
| Epigenetics and DNA Methylation | Lifetime | 472 | CN 28 | 98.81 |
| Immune Response and Inflammation | Lifetime | 451 | CN 10 | 98.85 |
| Phagocytosis and Immune Regulation | Lifetime | 87 | CN 4 | 98.06 |
| Drug Transport and Resistance Mechanisms | Lifetime | 548 | CN 16 | 97.69 |
| Endoplasmic Reticulum Stress and Disease | Lifetime | 366 | CN 12 | 97.51 |
| Circular RNAs in diseases | Lifetime | 460 | CN 245 | 97.23 |
| interferon and immune responses | Lifetime | 470 | CN 40 | 96.97 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 557 | CN 17 | 95.56 |
| Heat shock proteins research | Lifetime | 709 | CN 22 | 93.63 |
| RNA modifications and cancer | 2021-2025 | 1 | CN 1 | 99.99 |
| Ferroptosis and cancer prognosis | 2021-2025 | 1 | CN 1 | 99.99 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 1 | CN 1 | 99.96 |
| Immune Response and Inflammation | 2021-2025 | 1 | CN 1 | 99.78 |
| Autophagy in Disease and Therapy | 2021-2025 | 3 | CN 1 | 99.79 |
| Inflammasome and immune disorders | 2021-2025 | 3 | CN 2 | 99.74 |
| interferon and immune responses | 2021-2025 | 6 | CN 1 | 98.95 |
| Advanced Glycation End Products research | 2021-2025 | 2 | CN 1 | 98.33 |
| Heme Oxygenase-1 and Carbon Monoxide | 2021-2025 | 2 | CN 1 | 98.13 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 5 | CN 2 | 98.90 |
| Phagocytosis and Immune Regulation | 2021-2025 | 7 | CN 2 | 97.76 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 11 | CN 3 | 98.35 |
| Ubiquitin and proteasome pathways | 2021-2025 | 36 | CN 12 | 97.70 |
| Epigenetics and DNA Methylation | 2021-2025 | 189 | CN 78 | 96.40 |
| Immune cells in cancer | 2021-2025 | 173 | CN 100 | 96.15 |
| Trace Elements in Health | 2021-2025 | 49 | CN 20 | 95.99 |
| Circular RNAs in diseases | 2021-2025 | 157 | CN 115 | 96.39 |
| Caveolin-1 and cellular processes | 2021-2025 | 17 | CN 4 | 85.44 |
| ATP Synthase and ATPases Research | 2021-2025 | 182 | CN 17 | 83.01 |
| Heat shock proteins research | 2021-2025 | 132 | CN 17 | 83.34 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 345 | CN 68 | 82.11 |
| Cell death mechanisms and regulation | 2021-2025 | 183 | CN 45 | 75.58 |
| Neonatal Health and Biochemistry | 2021-2025 | 500 | CN 31 | 72.46 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 963 | CN 289 | 73.93 |
| Calcium signaling and nucleotide metabolism | 2021-2025 | 205 | CN 30 | 70.96 |
| Immune responses and vaccinations | 2021-2025 | 535 | CN 39 | 67.16 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 602 | CN 204 | 66.54 |
